ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Impact on Wound Healing Events After Early Conversion to Everolimus in De Novo Renal Transplant Recipients: 24-Month Results from the Randomized ELEVATE Study.

B. Nashan,1 M. van der Giet,1 H. Holdaas,1 M. Zeier,1 J. Pascual,1 Y. Avihingsanon,1 P. Lopez,2 J. Aguilar-Sanchez,2 J. Kochuparampil,2 Z. Wang,3 J. Cruzado,1 J. De Fijter.1

1ELEVATE Study Group, Hamburg, Germany
2Novartis, Basel, Switzerland
3Novartis Pharmaceutical Corporation, East Hanover.

Meeting: 2016 American Transplant Congress

Abstract number: B106

Keywords: Calcineurin, Immunosuppression, Kidney transplantation, Safety

Session Information

Session Name: Poster Session B: Drug Minimization

Session Type: Poster Session

Date: Sunday, June 12, 2016

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Background

Wound healing events (WHE) are probably the most common type of post-transplant (Tx) surgical complication. Due to its antiproliferative properties, mammalian target of rapamycin inhibitors may affect wound healing process. Here we evaluate the incidence of WHE at 24-months (M) post-Tx, from the ELEVATE study.

Methods

ELEVATE (NCT01114529) was a 24M, open-label, multicenter study, in which de novo kidney Tx recipients were randomized at 10-14 weeks post-Tx to receive either EVR (n=360; trough level [C0] 6-10 ng/mL) or continue standard CNI regimen (n=357; C0: TAC 5-10 ng/mL or CsA 100-250 ng/mL); all patients received enteric-coated mycophenolate sodium and steroids. Incidence of patients with WHE was summarized by treatment arm and baseline body mass index (BMI) quartile.

Results

At M24, incidence of WHE was similar in both the arms (EVR, 6.6 vs. CNI, 5.8%; P=0.662); although it varied within CNI arms (TAC, 7.6%; P=0.670 vs. CsA, 2.5%; P=0.085). Fluid collection was the most commonly reported WHE in EVR arm (n=5, 1.4% vs. CNI arm: n=1, 0.3%).

A total of 60 lymphocele events were reported in the run-in period prior to randomization.

The incidence of patients with WHE was similar in ≤25 percentile BMI category (EVR, 0.9 vs. CNI, 0.8%; P=0.846). However, the incidence was higher in EVR arm in >25–≤50 (2.6 vs. 1.1%; P=0.271) and significantly higher in >50–≤75 categories (2.0 vs. 0.6%; P=0.049).

Incidence of patients free from WHE was similar in both arms (EVR, Kaplan-Meier estimates 94.7%; 95%CI: 92.3, 97.1 vs. CNI, 93.7%; 95%CI: 91.0, 96.4; P=0.615).

Conclusions

Incidence of patients with WHE was low and comparable between the treatment arms. However, the combination of two anti-proliferative substances may present a risk for the development of de novo fluid collections of unknown origin more than 3M after surgery, especially for patients with a high BMI risk factor.

CITATION INFORMATION: Nashan B, van der Giet M, Holdaas H, Zeier M, Pascual J, Avihingsanon Y, Lopez P, Aguilar-Sanchez J, Kochuparampil J, Wang Z, Cruzado J, De Fijter J. Impact on Wound Healing Events After Early Conversion to Everolimus in De Novo Renal Transplant Recipients: 24-Month Results from the Randomized ELEVATE Study. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Nashan B, Giet Mvander, Holdaas H, Zeier M, Pascual J, Avihingsanon Y, Lopez P, Aguilar-Sanchez J, Kochuparampil J, Wang Z, Cruzado J, Fijter JDe. Impact on Wound Healing Events After Early Conversion to Everolimus in De Novo Renal Transplant Recipients: 24-Month Results from the Randomized ELEVATE Study. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/impact-on-wound-healing-events-after-early-conversion-to-everolimus-in-de-novo-renal-transplant-recipients-24-month-results-from-the-randomized-elevate-study/. Accessed May 9, 2025.

« Back to 2016 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences